PLA2 Receptor Antibody Test

The PLA2 Receptor Antibody test is a specialised blood investigation used primarily in the evaluation and monitoring of membranous nephropathy. It detects circulating autoantibodies directed against the M-type phospholipase A2 receptor, commonly abbreviated as PLA2R. This receptor is present on podocytes, the specialised cells that help form the filtering barrier within the kidney's glomeruli.

Anti-PLA2R antibodies are strongly associated with primary or autoimmune membranous nephropathy. Detection of these antibodies in a patient with a compatible clinical presentation can provide valuable diagnostic information. Antibody levels may also help assess immunological disease activity, monitor treatment response and identify possible relapse. The result must still be interpreted with urine protein measurements, kidney-function tests, serum albumin, clinical findings and, when required, kidney biopsy results.

What Is the PLA2 Receptor?

PLA2R stands for M-type phospholipase A2 receptor. It is a transmembrane protein expressed on podocytes, which are highly specialised cells located along the outer surface of glomerular capillaries. Podocytes and the glomerular basement membrane play an essential role in preventing excessive protein from leaking from the blood into the urine.

In PLA2R-associated membranous nephropathy, the immune system produces antibodies that recognise PLA2R as a target. Antibody binding and immune-complex formation can damage the kidney's filtration barrier. This damage may allow large amounts of albumin and other proteins to pass into the urine.

What Is Membranous Nephropathy?

Membranous nephropathy is a glomerular kidney disease characterised by immune deposits along the glomerular basement membrane. These deposits can cause thickening and dysfunction of the filtration barrier. The condition is an important cause of nephrotic syndrome in adults, although presentation and severity vary between individuals.

Some patients experience spontaneous improvement, while others develop persistent proteinuria, complications of nephrotic syndrome or progressive loss of kidney function. The clinical course is assessed using proteinuria, serum albumin, estimated glomerular filtration rate, creatinine, antibody levels and other risk factors.

Primary Membranous Nephropathy

Primary membranous nephropathy is usually an autoimmune disease in which antibodies target an antigen associated with podocytes. PLA2R is the most frequently recognised target. Circulating anti-PLA2R antibodies are found in approximately 70% to 75% of patients with primary membranous nephropathy, depending on the population, disease activity and assay used.

Secondary Membranous Nephropathy

Membranous nephropathy can also occur in association with another disease or exposure. Potential secondary causes include autoimmune disorders, chronic infections, selected medicines and malignancy. Anti-PLA2R antibodies are less commonly associated with secondary forms, but their presence does not eliminate the need for an appropriate clinical evaluation.

The treating nephrologist determines which investigations are necessary based on the patient's age, symptoms, history, examination and laboratory findings. The PLA2R antibody result should not be used as the sole basis for labelling disease as primary or secondary.

Why Is the PLA2 Receptor Antibody Test Performed?

The test may be ordered to support the diagnosis of PLA2R-associated membranous nephropathy in a patient with nephrotic syndrome or unexplained heavy proteinuria. It can also help distinguish primary membranous nephropathy from certain alternative causes of nephrotic syndrome when considered with other clinical and laboratory information.

For patients with known PLA2R-positive membranous nephropathy, quantitative or serial antibody testing may help monitor disease activity. Falling or disappearing antibody levels can indicate an immunological response, while persistent or increasing concentrations may suggest ongoing antibody activity, inadequate response or relapse.

Who May Need This Test?

A nephrologist may recommend this test for a patient with significant protein in the urine, nephrotic-range proteinuria, low serum albumin, unexplained body swelling, foamy urine or a clinical picture suggestive of membranous nephropathy. It may also be ordered after a kidney biopsy demonstrates membranous nephropathy.

Patients already diagnosed with PLA2R-associated membranous nephropathy may require repeat testing during observation or treatment. Testing may also be considered before and after kidney transplantation because membranous nephropathy can recur in a transplanted kidney in some patients.

Symptoms That May Lead to Testing

Membranous nephropathy may be detected after routine urine testing shows proteinuria. When symptoms occur, they may include swelling around the eyes, swelling of the legs or ankles, weight gain caused by retained fluid, foamy urine, fatigue and reduced appetite.

Nephrotic syndrome can also increase blood lipids and the risk of blood clots or infection. These symptoms and complications are not specific to membranous nephropathy. Other kidney, liver, cardiac and systemic conditions can cause similar findings, so a complete medical evaluation is necessary.

Sample Required

The PLA2 Receptor Antibody test usually requires a serum sample. A healthcare professional collects venous blood, most often from a vein in the arm, into an appropriate tube. The laboratory separates the serum from the blood cells and analyses it for anti-PLA2R antibodies.

The blood collection procedure usually takes only a few minutes. Temporary discomfort, bruising, light-headedness or slight bleeding may occur. Serious complications from routine venous blood collection are uncommon.

Preparation Before the Test

Fasting is generally not required for an isolated PLA2 receptor antibody test. Patients may usually eat normally and drink water before collection unless other tests ordered at the same time require fasting.

Tell the doctor about all medicines, including steroids, rituximab, cyclophosphamide, calcineurin inhibitors and other immunosuppressive treatments. Recent immunosuppressive therapy may lower circulating antibody levels. Do not stop or alter prescribed treatment without instructions from the treating nephrologist.

How Is the Test Performed?

Anti-PLA2R antibodies may be measured using an enzyme-linked immunosorbent assay or detected through indirect immunofluorescence. Some laboratory pathways use an initial quantitative or semi-quantitative ELISA and perform immunofluorescence when the result is negative or borderline but clinical suspicion remains.

ELISA results may be reported in relative units per millilitre, while immunofluorescence testing may be reported as negative, positive or as a titre. Methods and cut-offs vary, so the laboratory-specific reference interval must be used.

Understanding the Test Results

Negative Result

A negative result means circulating anti-PLA2R antibodies were not detected above the assay threshold. It does not rule out primary membranous nephropathy. Some affected patients are PLA2R antibody negative, particularly during immunological remission, after immunosuppressive treatment or when another podocyte antigen is involved.

If membranous nephropathy remains suspected, the nephrologist may recommend kidney biopsy, tissue staining for PLA2R, immunofluorescence testing, testing for other associated antigens or antibodies, and investigation for secondary causes.

Borderline Result

A borderline result is close to the assay cut-off and may require confirmation by another method, repeat sampling or correlation with kidney biopsy findings. The clinical significance depends on the patient's proteinuria, serum albumin, kidney function and pre-test probability of membranous nephropathy.

Positive Result

A positive anti-PLA2R antibody result in a patient with nephrotic syndrome and a compatible clinical presentation strongly supports PLA2R-associated primary membranous nephropathy. However, the result should not be interpreted in isolation. The doctor will evaluate kidney function, proteinuria and possible associated conditions.

A positive result does not automatically indicate how much permanent kidney damage has occurred. Antibody concentration reflects immunological activity, while proteinuria and estimated glomerular filtration rate provide additional information about clinical kidney involvement.

Relationship Between Antibody Levels and Disease Activity

Anti-PLA2R antibody levels often correlate with immunological disease activity. Higher concentrations may be associated with active disease and a lower probability of spontaneous remission, although individual outcomes vary. Decreasing antibody levels can indicate that the autoimmune process is responding to treatment.

Changes in antibody concentration may occur before visible changes in urine protein. This difference is important because immunological remission may precede clinical remission. Proteinuria may take additional months to improve while the glomerular filtration barrier recovers.

Conversely, rising antibody levels may precede increasing proteinuria or clinical relapse. Serial results should ideally be obtained using the same testing method and laboratory to improve comparability.

Monitoring Treatment Response

Patients with PLA2R-positive membranous nephropathy may undergo repeat antibody testing after treatment or during follow-up. A substantial decline or disappearance of antibodies can support an immunological response. Persistently high or increasing antibodies may lead the nephrologist to reassess disease activity, treatment adherence or the management strategy.

Treatment must never be changed solely because of one antibody result. The doctor considers proteinuria, serum albumin, creatinine, estimated glomerular filtration rate, side effects and the patient's overall risk of disease progression.

PLA2R Antibodies and Kidney Biopsy

Kidney biopsy has traditionally been central to diagnosing membranous nephropathy. It can confirm the pattern of glomerular injury, evaluate chronic damage and identify findings suggesting another kidney disease.

Current kidney guidelines indicate that a kidney biopsy may not always be required to confirm membranous nephropathy in an adult with nephrotic syndrome, preserved or appropriately assessed kidney function, a positive anti-PLA2R antibody result and a compatible clinical context. However, biopsy may still be necessary when the presentation is unusual, kidney function is declining, another disease is suspected or additional diagnostic information would affect management.

Evaluation for Secondary Causes

Even when anti-PLA2R antibodies are present, clinicians may assess for associated diseases according to the patient's history and risk factors. Evaluation can include testing for infections, autoimmune disorders, medication-related causes and age-appropriate cancer screening.

A positive PLA2R antibody result should not be used to avoid clinically appropriate screening. The investigation plan must be individualised by the nephrologist.

Related Tests

• Urine routine examination and urine protein measurement
• Urine protein-to-creatinine ratio or 24-hour urine protein
• Serum creatinine and estimated glomerular filtration rate
• Serum albumin and total protein
• Blood lipid profile
• Complement C3 and C4 levels
• Antinuclear antibody and other autoimmune investigations
• Screening for hepatitis B, hepatitis C and other infections when indicated
• THSD7A antibody testing in selected PLA2R-negative cases
• Kidney biopsy with immunostaining when clinically required

Factors That May Affect Interpretation

• Current immunological activity of the kidney disease
• Recent or ongoing immunosuppressive treatment
• Spontaneous immunological remission
• Timing of collection in relation to symptoms and treatment
• ELISA or immunofluorescence methodology
• Laboratory-specific cut-off values
• Presence of membranous nephropathy related to another antigen
• Kidney biopsy findings and clinical probability

Important Test Limitations

A negative anti-PLA2R result does not exclude membranous nephropathy. Approximately one-quarter or more of patients with primary membranous nephropathy may lack detectable circulating antibodies, depending on the assay and timing. Other target antigens may be involved.

A positive result supports PLA2R-associated disease but should not replace clinical assessment. The test cannot independently determine the degree of kidney scarring, exact thrombotic risk, need for anticoagulation or the best immunosuppressive treatment.

Antibody results from different laboratories may not be directly comparable. Serial monitoring is most useful when the same method and laboratory are used. Clinical decisions should be made by a nephrologist familiar with the patient's complete medical history.

When to Seek Urgent Medical Care

Seek urgent medical attention for sudden breathlessness, chest pain, coughing blood, painful swelling in one leg, sudden weakness, speech difficulty or another possible symptom of a blood clot. Patients with nephrotic syndrome can have an increased risk of thrombosis.

Urgent medical assessment is also required for rapidly worsening swelling, severely reduced urine output, blood in urine, persistent vomiting, confusion or severe breathlessness. Do not wait for a PLA2R antibody report when emergency symptoms are present.

Clinical Interpretation Note

The PLA2 Receptor Antibody test is a valuable biomarker for PLA2R-associated membranous nephropathy. A positive result can strongly support the diagnosis in a compatible clinical setting, while serial concentrations can help assess immunological response. Nevertheless, the result must be interpreted with urine protein, serum albumin, kidney function, clinical findings and specialist assessment.

Booking the PLA2 Receptor Antibody Test

The PLA2 Receptor Antibody test is available through Focus Diagnostics for ₹5600. Before collection, confirm the serum requirement, assay method, expected reporting schedule and whether a quantitative value, titre or reflex test is included. This information is educational and does not replace personalised advice from a nephrologist or another qualified healthcare professional.